Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Twin Study Suggests Epigenetic Differences in AD
21 August 2009. As is true with getting into college or receiving a job offer, it’s not just pedigree but also life experiences that may determine whether a person will develop Alzheimer disease. So suggests an analysis of identical twins—one who died of AD, one without AD—reported this month in the publicly accessible journal PLoS ONE. Researchers led by Paul Coleman, Sun Health Research Institute, Sun City, Arizona, examined postmortem brain tissue and found that cortical neurons from the AD twin had reduced DNA methylation, a biochemical process that can disrupt genes’ accessibility for transcription by attaching methyl groups to individual nucleotides.

In an earlier study (Mastroeni et al., 2008), first author Diego Mastroeni and colleagues found lower levels of DNA methylation, as well as reduced expression of DNA methyltransferase and other methylation regulators, in affected brain areas of sporadic AD patients. “This led to the question of whether these epigenetic effects we saw in AD were related to the [people’s] genes or to their life experience,” said Coleman, who is also a professor emeritus at the University of Rochester Medical Center, New York. In the sporadic AD study, genetic backgrounds were all over the map—which is why the scientists leaped at the opportunity to analyze epigenetic markers in identical twins discordant for AD. “This was a situation in which the genetic background would be quite similar, if not identical, and anything we saw could be attributed to life experience,” Coleman said. Other research has shown that identical twins who are genetically prone to AD can differ markedly in their age of onset and degree of pathology (Brickell et al., 2007).

The twins in the current study were white males who attended the same schools and worked as chemical engineers. One encountered extensive pesticides in his work and died at age 76 after a 16-year battle with Alzheimer disease. The other worked in a different environment and was cognitively normal when he died of prostate cancer at age 79. Pathologically, their brains could not have looked more different. At the time of his death, the twin with AD had an anterior temporal neocortex riddled with amyloid plaques and neurofibrillary tangles, the two key pathological hallmarks of AD. In his non-demented brother, however, “we had to hunt through the brain sections in order to find even one neurofibrillary tangle,” Coleman told ARF. The cognitively intact man also had comparatively higher expression of 5-methylcytosine, a marker of methylated cytosine-guanine (CpG) sites on DNA, in neurons, reactive astrocytes, and microglia of brain areas typically vulnerable to AD.

Apart from disease status, DNA methylation appears to vary with age and environmental factors. In a recent analysis of 217 non-pathological human tissues, published this month in PLoS Genetics (Christensen et al., 2009), researchers report that genes in CpG islands become increasingly methylated as people get older, whereas genes outside of these methylation hotspots lose methylation with age. Methylation status also correlated with environmental exposures such as tobacco smoking in that analysis, led by Karl Kelsey at Brown University. In an earlier study, Manel Estreller and colleagues at the Spanish National Cancer Center, Madrid, analyzed identical twins and found that DNA methylation status was very similar when the siblings were young but diverged more and more as they got older (Fraga et al., 2005). Those papers “make the case for environmental and aging effects on methylation,” Coleman said of the Estreller and Kelsey studies. “Our research shows that the concept of life events affecting DNA methylation may apply to development of the AD phenotype. It also stresses the potential importance of epigenetic phenomena in molecular mechanisms of AD.”

The new data may have ramifications for interpreting studies of AD genetics. “One study will find that, yes, this gene is a risk factor for AD, and others say, no, it’s not, and the statistics have some uncertainty in them,” Coleman said. “We raise the question of whether the probabilistic nature of the relationship between some genes and AD may be due to the fact that the genetic effects can be modulated by life experience.”

A recent study in Iceland may offer a case in point. Researchers at the University of Iceland and at deCODE Genetics, Reykjavik, reported a drastically shortened lifespan over the last 20 years in people with a hereditary amyloid angiopathy, and attribute this to diet changes that may have exacerbated the effects of a genetic mutation tied to the disease (Palsdottir et al., 2008 and ARF related news story). Studies in AD mouse models that overexpress mutant amyloid precursor protein (TgCRND8 and 129Sv) offer another example of a diet-gene interaction. When put on a diet deficient in folate, B1, and B6, the AD mice had reduced brain methylation activity in conjunction with amyloid-β overproduction and cognitive impairment (Fuso et al., 2008).

A link between epigenetics and AD also came up in a recent investigation led by Axel Schumacher at the Klinikum Rechts der Isar, Munich, Germany. However, unlike the current study, which reveals global demethylation in affected brain areas of the AD twin, Schumacher’s showed that most DNA methylation changes in AD brains are subtle and restricted to specific genes, including several involved in amyloid-β processing (PSEN1, ApoE) and methylation homeostasis (MTHFR, DNMT1) (Wang et al., 2008 and ARF related news story). In an e-mail to ARF, Schumacher noted that analyzing late-stage disease tissue makes it hard to determine whether the observed epigenetic phenotypes are the cause or the result of the disease. In the new study, “the global demethylation in the affected brain areas may indicate that specific components of the epigenetic machinery, such as DNA maintenance methylation, were inactivated, which in turn could indicate that the observed epigenetic patterns result from the course of the disease,” he wrote (see full comment below).

Coleman hopes to address this possibility in a genomewide study to identify specific genes affected by DNA methylation in AD, he told ARF. Future work in this area may benefit from a new approach that uses flow cytometry and state-of-the-art sequencing techniques to quantify the number of methylated molecules in a sample. Its developers show the method is sensitive enough to detect one methylated molecule in about approximately 5,000 unmethylated molecules in DNA from plasma or fecal samples. In a report published online 16 August in Nature Biotechnology (Li et al., 2009), researchers led by Sanford Markowitz, Case Western Reserve University, Cleveland, Ohio, and Bert Vogelstein at Johns Hopkins University School of Medicine, Baltimore, Maryland, have used the technology to detect early-stage colorectal cancer.—Esther Landhuis.

Reference:
Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD. Epigenetic Differences in Cortical Neurons from a Pair of Monozygotic Twins Discordant for Alzheimer’s Disease. Aug 2009. PLoS ONE 4(8). Abstract

 
Comments on News and Primary Papers
  Primary Papers: Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease.

Comment by:  Axel Schumacher
Submitted 21 August 2009  |  Permalink Posted 21 August 2009

There are many observations, including from our own laboratory, that indicate that epigenetic drift is likely to be a substantial mechanism predisposing individuals to LOAD and contributing to the course of disease. In this context, the study by Mastroeni et al. is a very interesting report, as we may gain more insight into epigenetic events in AD. However, in my opinion, the study presents a potentially unusual epigenetic phenotype in the affected co-twin. In a previous study from our group (Wang et al., 2008), we were able to show that most DNA methylation changes in AD brains are restricted to specific genes and are rather subtle. In this new study of discordant twins, the authors found significant global demethylation in the affected brain areas of the AD twin. In general, such rare monozygotic twins discordant for a disease offer a great opportunity to study molecular events that may contribute to a predisposition or the development of a complex disease such as AD. And indeed, this observation is highly interesting as it...  Read more

  Primary Papers: Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease.

Comment by:  Paul Coleman, ARF Advisor
Submitted 24 August 2009  |  Permalink Posted 25 August 2009

Dr. Schumacher’s commentary about our paper makes a number of valid points that, in their totality, emphasize that there is much still to be learned about epigenetics with regard to the normally aging and Alzheimer brain. For example, he refers to “epigenetic drift” and “stochastic fluctuations,” phrases that imply a random process. We, on the other hand, prefer to use the term “life events,” which implies a causal connection between specific events and epigenetic consequences. Such causal connection is consistent with the work of Fuso et al. (2008), which shows that “PS1 and BACE genes can be upregulated even in vivo by B vitamin deficiency, a condition that limits methylation activity.” Of course, what is missing here is the demonstration that the experimental B vitamin deficiency led to decreased DNA methylation (or other epigenetic regulator) of the specific genes affected in their animals.

The hypothesis that life events, rather than a stochastic process, influence epigenetic phenomena is also consistent with the comment in Fraga et al. (2005) that similarities in the...  Read more


  Comment by:  Andrea Fuso (Disclosure)
Submitted 31 August 2009  |  Permalink Posted 1 September 2009

After reading with great interest the comment by Dr. Schumacher and the response by Dr. Coleman, I'd like to point out that the demonstration that B vitamin deficiency led to decreased DNA methylation (missing in our 2008 paper) was actually given in our recent paper on PS1 promoter demethylation (Fuso et al., 2009).

I completely agree with the conclusion that there is much more to understand in the area of epigenetic changes in LOAD. It seems to me of great importance that different approaches are applied by different groups to investigate this topic.

References:
Fuso A, Nicolia V, Pasqualato A, Fiorenza MT, Cavallaro RA and Scarpa S. Changes in Presenilin 1 gene methylation pattern in diet-induced B vitamin deficiency. Neurobiol Aging 2009. Abstract

View all comments by Andrea Fuso

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad